标题
JAK Inhibitors: Treatment Efficacy and Safety Profile in Patients with Psoriasis
作者
关键词
-
出版物
Journal of Immunology Research
Volume 2014, Issue -, Pages 1-7
出版商
Hindawi Limited
发表日期
2014-05-06
DOI
10.1155/2014/283617
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Psoriasis prevalence among adults in the United States
- (2014) Tara D. Rachakonda et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis
- (2013) Joel Kremer et al. ANNALS OF INTERNAL MEDICINE
- Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study
- (2013) Désirée van der Heijde et al. ARTHRITIS AND RHEUMATISM
- Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment
- (2013) B. Strober et al. BRITISH JOURNAL OF DERMATOLOGY
- A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis
- (2013) W.C. Ports et al. BRITISH JOURNAL OF DERMATOLOGY
- Jakpot! New small molecules in autoimmune and inflammatory diseases
- (2013) Kamran Ghoreschi et al. EXPERIMENTAL DERMATOLOGY
- Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial
- (2013) Gerd R Burmester et al. LANCET
- Tofacitinib
- (2013) Drugs in research & development
- Coronary Artery Disease in Patients With Psoriasis Referred for Coronary Angiography
- (2012) April W. Armstrong et al. AMERICAN JOURNAL OF CARDIOLOGY
- Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years
- (2012) A.B. Kimball et al. BRITISH JOURNAL OF DERMATOLOGY
- Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study
- (2012) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Risk of Tuberculosis Reactivation With Tofacitinib (CP-690550)
- (2012) Mamoudou Maiga et al. JOURNAL OF INFECTIOUS DISEASES
- Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis
- (2012) Naresh Punwani et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Kinase Inhibition — A New Approach to the Treatment of Rheumatoid Arthritis
- (2012) David A. Fox NEW ENGLAND JOURNAL OF MEDICINE
- Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
- (2012) Roy Fleischmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
- (2012) Ronald F. van Vollenhoven et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis
- (2012) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone
- (2011) Joel M. Kremer et al. ARTHRITIS AND RHEUMATISM
- Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs
- (2011) Roy Fleischmann et al. ARTHRITIS AND RHEUMATISM
- Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)
- (2011) Kamran Ghoreschi et al. JOURNAL OF IMMUNOLOGY
- Preclinical Evaluation of Local JAK1 and JAK2 Inhibition in Cutaneous Inflammation
- (2011) Jordan S. Fridman et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Signal transduction pathways and transcriptional regulation in Th17 cell differentiation
- (2010) Kiyoshi Hirahara et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis
- (2010) Debra M Meyer et al. Journal of Inflammation-London
- Janus kinases in immune cell signaling
- (2009) Kamran Ghoreschi et al. IMMUNOLOGICAL REVIEWS
- JAK3 Inhibition Significantly Attenuates Psoriasiform Skin Inflammation in CD18 Mutant PL/J Mice
- (2009) B. Y. Chang et al. JOURNAL OF IMMUNOLOGY
- IL-6 Signaling in Psoriasis Prevents Immune Suppression by Regulatory T Cells
- (2009) W. A. Goodman et al. JOURNAL OF IMMUNOLOGY
- Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Pharmacologic Effect of CP-690,550 in Patients With Psoriasis
- (2009) Mary G. Boy et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Psoriasis
- (2009) Frank O. Nestle et al. NEW ENGLAND JOURNAL OF MEDICINE
- Th17 cells: a new fate for differentiating helper T cells
- (2008) Zhi Chen et al. IMMUNOLOGIC RESEARCH
- Therapeutic targeting of Janus kinases
- (2008) Marko Pesu et al. IMMUNOLOGICAL REVIEWS
- The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: Results from NHANES 2003-2004
- (2008) Shanu Kohli Kurd et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
- (2007) Alan Menter et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started